Anu Hoey is Chief Business Officer at Sensei Biotherapeutics, a company focused on using its ImmunoPhageÔ platform to develop important therapeutics to treat cancer patients. Ms. Hoey has over 20 years of experience in corporate strategy and business transactions for innovative biotechnology companies. Previously, Ms. Hoey served as Chief Business Officer of Second Genome, Inc. where she led corporate strategy, business development, communications, and led the transformative multi-year discovery and biomarker deal with Gilead Corporation. Prior to Second Genome, Ms. Hoey served at Chief Business Officer of Invenra, Inc. where she helped develop business strategy around a multi-specific antibody platform, implemented IP strategy and executed a large, strategic deal. Ms. Hoey also served as VP of Business development at Arcus biosciences and Sr. Director of business development at Sutro Biopharma where she executed multiple deals and help lead manufacturing strategy. Ms. Hoey has an M.B.A. from the University of San Francisco, an M.S. in Molecular Virology from Case Western Reserve University and a B.S. in Molecular Genetics from The Ohio State University.